Novartis AG v. Union of India (2013)
Supreme Court of India · (2013) 6 SCC 1
Summary
The Supreme Court interpreted Section 3(d) of the Patents Act, 1970 in the context of a pharmaceutical patent application and emphasised that a new form of a known substance must satisfy the statutory requirement of enhanced therapeutic efficacy.
Facts
- Novartis sought patent protection for a beta-crystalline form of imatinib mesylate.
- The application was rejected under the statutory patentability framework, including Section 3(d), and the dispute reached the Supreme Court.
Issues
- Whether the claimed crystalline form satisfied Section 3(d).
- How enhanced efficacy is to be assessed for a new form of a known substance.
Provisions involved
- Patents Act, 1970 — s. Section 3(d) — What are not inventions
Reasoning
Enhanced therapeutic efficacy
For the relevant pharmaceutical new-form claim, the statutory standard focuses on enhanced therapeutic efficacy rather than every form of increased physical or chemical property.
Anti-evergreening function
Section 3(d) operates as a substantive patentability filter against extending monopoly protection to new forms of known substances without the required efficacy improvement.
Decision
The patent claim was rejected under Section 3(d).
Ratio decidendi
Section 3(d) must be applied as enacted and requires the claimed new form to cross the statutory threshold of enhanced therapeutic efficacy.
Exam points
- Section 3(d).
- Enhanced therapeutic efficacy.
- Pharmaceutical patentability and evergreening.
Tags: AIBE, Judiciary, Patent, Section 3(d), IPR